Glucagon-like peptide-1 (GLP-1) compounds have emerged as a compelling therapeutic strategy for managing metabolic syndromes. These naturally occurring hormones are secreted by the gut in response to meal intake, stimulating insulin production and suppressing glucagon release. GLP-1 derivatives exhibit promising therapeutic results in treating type